Author

J. Fontenot

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:non-human primate· 5 Research Focus:host-pathogen & immune response· 4 Research Focus:drug response / drug discovery· 3 Organism:mouse· 2 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

B. Pulendran· 3 shared K. Russell-Lodrigue· 3 shared L. Shirreff· 3 shared N. Golden· 3 shared A. C. Walls· 2 shared D. E. Ferrell· 2 shared D. T. O Hagan· 2 shared F. J. Villinger· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

B. Pulendran

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Ca2+/Calmodulin Dependent Protein Kinase Kinase-2 (CaMKK2) promotes Protein Kinase G (PKG)-dependent actin cytoskeletal assembly to increase tumor metastasis

D. Mukherjee, R. A. Previs, C. N. Haines, M. Al Abo, P. K. Juras, K. C. Strickland, B. Chakraborty, S. Artham, R. Whitaker, K. L. Hebert, J. Fontenot, S. R. Patierno, J. A. Freedman, F. H. Lau, M. Burow, , D. P. McDonnell

This study identifies CaMKK2 as a driver of tumor metastasis through a novel signaling pathway involving PDE1A, PKG1, and VASP, suggesting it as a therapeutic target for TNBC and HGSOC.

bioRxiv · Apr 17, 2023 · PreprintCancer Biology

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

P. A.- B. Weidenbacher, M. Sanyal, N. Friedland, S. Tang, P. S Arunachalam, M. Hu, O. S. Kumru, M. K. Morris, J. Fontenot, L. Shirreff, J. Do, Y.-C. Cheng, G. Vasudevan, M. B. Feinberg, F. J. Villinger, , P. S. Kim

This paper describes a ferritin-based nanoparticle vaccine, DCFHP-alum, that induces strong, long-lasting neutralizing antibodies against SARS-CoV-2 variants in non-human primates.

bioRxiv · Dec 25, 2022Immunology

Programming the lymph node immune response with Amphiphile-CpG induces potent cellular and humoral immunity following COVID-19 subunit vaccination in mice and non-human primates

L. M. Seenappa, A. Jakubowski, M. P. Steinbuck, E. Palmer, C. M. Haqq, C. Carter, J. Fontenot, F. Villinger, L. K. McNeil, P. C. DeMuth

This study evaluates an AMP-CpG adjuvant in combination with SARS-CoV-2 RBD as a subunit vaccine, showing enhanced T cell and cross-reactive antibody responses in mice and NHPs.

bioRxiv · May 19, 2022 · PreprintImmunology

Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine

P. S. Arunachalam, Y. Feng, U. Ashraf, M. Hu, V. V. Edara, V. I. Zarnitsyna, P. P. Aye, N. Golden, K. W. M. Green, B. M. Threeton, N. J. Maness, B. J. Beddingfield, R. P. Bohm, J. Dufour, K. Russell-Lodrigue, , B. Pulendran

This study shows that an adjuvanted subunit vaccine provides durable protection against SARS-CoV-2 Omicron in non-human primates, with strong neutralizing antibodies and memory T/B cells after booster doses.

bioRxiv · Mar 18, 2022 · PreprintImmunology

Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates

S. Pillet, P. S. Arunachalam, G. Andreani, N. Golden, J. Fontenot, P. Aye, K. Röltgen, G. Lehmick, C. Dube, P. Gobeil, S. Trepanier, N. Charland, M.-A. D'Aoust, K. Russell-Lodrigue, R. V. Blair, , N. Landry

This study evaluates the safety and immunogenicity of a plant-derived VLP vaccine against SARS-CoV-2 in non-human primates, finding that AS03 adjuvanted vaccine provides better protection and immune response.

bioRxiv · May 15, 2021Immunology

Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

P. S Arunachalam, A. C. Walls, N. Golden, C. Atyeo, S. Fischinger, C. Li, P. Aye, M. J. Navarro, L. Lai, V. V. Edara, K. Roltgen, K. Rogers, L. Shirreff, D. E. Ferrell, S. Wrenn, , Coffma

This study evaluates adjuvants for a subunit SARS-CoV-2 nanoparticle vaccine in non-human primates, showing durable neutralizing antibody responses and protection against infection.

bioRxiv · Feb 10, 2021 · PreprintImmunology